Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spero Therapeutics, Inc. (NASDAQ: SPRO) on behalf of long-term stockholders following a class action complaint that was filed against Spero with a Class Period from October 28, 2021 to May 2, 2022. Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Spero securities between October 28, 2021 and May 2, 2022, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/spro.
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) securities between May 6, 2021 and May 2, 2022, inclusive (the “Class Period”).
Shareholder rights law firm Robbins LLP is investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) and its officers and directors to determine whether they breached fiduciary duties or violated securities laws in making misstatements regarding FDA approval of one of its lead product candidates.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022, inclusive (the “Class Period”).
San Diego, CA -- (SBWIRE) -- 06/09/2022 -- An investor, who purchased shares of Spero Therapeutics, Inc. (NASDAQ:SPRO), filed a lawsuit in the over alleged Securities Laws violations by Spero Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Law Offices of Howard G. Smith reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022, inclusive (the “Class Period”).
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022, inclusive (the “Class Period”). Spero investors have until July 25, 2022 to file a lead plaintiff motion.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022, inclusive (the “Class Period”). Spero investors have until July 25, 2022 to file a lead plaintiff motion.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022, inclusive (the “Class Period”). Spero investors have until July 25, 2022 to file a lead plaintiff motion.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) investors concerning the Company’s possible violations of the federal securities laws.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Spero securities between October 28, 2021 and May 2, 2022, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/spro.
Law Offices of Howard G. Smith announces an investigation on behalf of Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Spero securities between October 28, 2021 and May 2, 2022, both dates inclusive (the “Class Period”). Investors have until July 25, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022. The complaint alleges violations of the Securities Exchange Act of 1934. Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spero Therapeutics, Inc. (“Spero” or “the Company”) (NASDAQ: SPRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spero Therapeutics, Inc. (“Spero” or “the Company”) (NASDAQ: SPRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spero Therapeutics, Inc. (NASDAQ: SPRO) between October 28, 2021 and May 2, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than July 25, 2022.
